

Osta Biotechnologies Inc.  
Press Release  
For Immediate Distribution

## **OSTA APPOINTS DR. ALAOUI-JAMALI TO ITS SCIENTIFIC ADVISORY BOARD**

**MONTREAL, QC – March 6, 2007 – Osta Biotechnologies Inc.** (TSX Venture: OBI) is pleased to announce the appointment of Dr. Moulay Alaoui-Jamali to its Scientific Advisory Board.

Dr. Alaoui-Jamali is a renowned Professor of Oncology and Medicine, Faculty of Medicine, McGill University. He is also the leader of the Drug Discovery Group at the Segal Comprehensive Cancer Center at the Jewish General Hospital. As a recognized authority in cancer research, Dr. Alaoui-Jamali has been engaged in basic and translational cancer research for many years. He has expertise in tumor biology, cancer pharmacology, experimental therapeutics, and cancer target discovery. He has published extensively in these areas and has been serving on several scientific panels and research committees, including the CIHR, NCIC, and the College of Reviewers for the Canada Research Chair Program. He has held numerous grants and awards, including from the NCIC, CIHR, FRSQ, NSRC, the Cancer Research Society, Department of Defense of the US Army Research Program, and Canada Foundation for Innovation.

Dr. Alaoui-Jamali received his Ph.D. in Molecular Cancer Pharmacology from the National Cancer Institute and René-Déscartes University and Faculty of Medicine Lariboisière-Saint-Louis (Sorbonne), Paris, France in 1986. He completed his post-doctoral training at the Cancer Centre, Roswell Park Memorial Institute, New York University in Buffalo, USA, and subsequently joined McGill University.

Dr. Alaoui-Jamali stated “I am very excited about the oncology programs under development at Osta and am extremely pleased to join Osta’s scientific advisory board”.

“It is a great pleasure and honor for us to have one of the world's leading authorities on oncology research and a renowned scientist like Dr. Alaoui-Jamali joining our Scientific Advisory Board. His addition to our team is very timely and synergistic to our new and exciting oncology program and is invaluable as he brings vast knowledge in oncology research as well as solid expertise in the development of chemotherapeutic agents” says Dr. Ajay Gupta, Osta’s Chairman & CEO.

### **About Osta Biotechnologies Inc.**

Osta is a biopharmaceutical company listed on the TSX Venture Exchange dedicated to developing novel diagnostics and therapeutics in the areas of Alzheimer’s disease, Osteoporosis, Cancer and X-linked hypophosphatemic rickets (XLH).

For further information, please contact:

Osta Biotechnologies Inc.  
Alain Geahchan  
Director of Operations  
Telephone: (514) 567-5505

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.

*Certain information in this press release is forward-looking and is subject to numerous risks and uncertainties. By their nature, such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. These risks include actions of Osta's competitors, and those inherent in scientific research and development.*

*The issue of this press release is limited to Canada only. This press release should not be issued in the United States through U.S. news wire agencies.*